Kairos Amends Helena Equity Line, Extends Term to 2028; Reports 17.7-Month PFS
KAPA is trading near its 52-week low of $0.418 (14% above the low).
Summary
Kairos amended its Helena equity line — 97% of VWAP pricing, one-day pricing period, term extended to December 31, 2028 — and presented interim Phase 2 data showing 17.7-month median PFS for ENV-105 plus apalutamide versus 2 months for apalutamide alone.
Key Events · Financing and Capital Events · KAPA
-
Equity Line Terms Loosened for Investor
Effective October 26, 2026, the purchase price is set at 97% of average daily VWAP during the Pricing Period, and the Pricing Period was shortened from three Trading Days to one Trading Day.
-
ELOC Term Extended to December 31, 2028
The Third Amendment, dated October 29, 2026, extends the option to use the Helena equity line an additional year, with the Commitment Period running until that date.
-
Interim Phase 2 PFS Separation
Median PFS was 17.7 months with ENV-105 plus apalutamide versus 2 months with apalutamide alone (P=0.0008), based on patients 1-10 in NCT05534646.
-
Trial Redesigned for Post-Enzalutamide Setting
The protocol modification shifts focus to first-line therapy after enzalutamide, with a larger randomized Part II comparing AR blockade plus carotuximab to AR blockade alone.
Analysis · KAPA · Life Sciences
Two developments land at once. First, the equity line of credit with Helena has been loosened in the buyer's favor: the purchase price is now 97% of VWAP (a 3% discount to market on every draw), and the pricing period was cut from three trading days to one, removing the averaging cushion that protected the company if the stock fell during a draw. With the term extended to December 31, 2028, the company has a standing, if expensive, source of cash for two more years. No shares were sold under these amendments — this is permission and terms, not a completed raise. Second, the interim Phase 2 readout in mCRPC is the more consequential item: median PFS of 17.7 months for ENV-105 plus apalutamide versus 2 months for apalutamide alone (P=0.0008) is a large separation, though it rests on a 10-patient safety lead-in and the trial is being redesigned to focus on first-line therapy after enzalutamide. For a company of this size, a credible efficacy signal is what drives value; the ELOC is what keeps the lights on while it is tested.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KAPA was trading at $0.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6M. The 52-week trading range was $0.42 to $7.70. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.